Menu

Explaining Elephants’ Cancer Resistance

Two studies reveal that the giant mammals have dozens of extra copies of a cancer-preventing gene.

Oct 13, 2015
Jef Akst

WIKIMEDIA, CHRISTOPHER MICHELWith about 100 times as many cells as a human, a 4,800-kilogram African elephant should, in theory, be more prone to accruing mutations that cause one of those cells to grow out of control. But elephants and other large mammals have surprisingly low rates of cancer, despite living for decades. As Joshua Schiffman, a pediatric oncologist at the University of Utah’s Huntsman Cancer Institute in Salt Lake City, and his colleagues found in a paper published last week (October 8) in JAMA, fewer than 5 percent of captive elephants worldwide die from cancer.

“Long-lived animals with lots of cells should all be dropping dead of cancer,” Schiffman told Science. “But they don’t or they’d go extinct.”

To understand why elephants are apparently cancer resistant, Schiffman and his colleagues scoured the genome of an African elephant and found 40 copies of the p53 gene, known to be important in cancer prevention. The Asian elephant genome contains between 30 and 40 copies of p53. Humans harbor only two copies of the gene. But elephant cells were no better at repairing DNA damage than human cells, in vitro experiments revealed. Instead, the researchers suggested that p53 helps elephants kill off precancerous cells before they become problematic.

Another study published last week (October 6) on the preprint server BioRxiv also found dozens of copies of p53 in the elephant genome, as well as in two extinct species of mammoth. Coauthor Vincent Lynch of the University of Chicago speculated that p53 duplicated as elephant ancestors began to grow in size, but noted that this is likely not the only mechanism to explain the lineage’s cancer resistance.

Cancer biologist Mel Greaves of the Institute for Cancer Research in London agreed. “What would happen if elephants smoked and had a bad diet,” he told Nature. “Would they really be protected from cancer? I doubt it.”

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.